Twist Bioscience (NASDAQ:TWST) Reaches New 1-Year Low After Insider Selling

Key Points

• Twist Bioscience (NASDAQ:TWST) hit a new 52-week low at $24.13 after CEO Emily M. Leproust sold 2,265 shares, signaling potential concerns over insider selling.
• Despite the recent price drop, analysts remain optimistic with an average price target of $49.40 and a "Moderate Buy" rating from nine research analysts.
• The company reported a revenue of $96.06 million for the recent quarter, outperforming estimates, but has a negative return on equity of 29.03% and forecasts an EPS of -2.12 for the current fiscal year.

Shares of Twist Bioscience Corporation (NASDAQ:TWST - Get Free Report) reached a new 52-week low on Wednesday after an insider sold shares in the company. The stock traded as low as $24.23 and last traded at $24.13, with a volume of 1350279 shares. The stock had previously closed at $25.09.

Specifically, CEO Emily M. Leproust sold 2,265 shares of Twist Bioscience stock in a transaction on Monday, September 8th. The stock was sold at an average price of $25.76, for a total transaction of $58,346.40. Following the completion of the sale, the chief executive officer owned 634,740 shares of the company's stock, valued at approximately $16,350,902.40. This trade represents a 0.36% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on TWST shares. Evercore ISI set a $46.00 target price on Twist Bioscience in a research report on Monday, August 4th. Cowen reissued a "buy" rating on shares of Twist Bioscience in a research note on Monday, August 4th. Nine research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $49.40.

Twist Bioscience Price Performance

The company has a fifty day moving average of $31.29 and a 200-day moving average of $34.55. The firm has a market cap of $1.46 billion, a P/E ratio of -16.70 and a beta of 2.31. The company has a debt-to-equity ratio of 0.03, a current ratio of 3.90 and a quick ratio of 3.60.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last announced its quarterly earnings results on Monday, August 4th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.54) by $0.07. The business had revenue of $96.06 million during the quarter, compared to the consensus estimate of $95.52 million. Twist Bioscience had a negative return on equity of 29.03% and a negative net margin of 23.51%. Twist Bioscience has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. On average, sell-side analysts anticipate that Twist Bioscience Corporation will post -2.12 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Osaic Holdings Inc. lifted its holdings in Twist Bioscience by 31.6% during the 2nd quarter. Osaic Holdings Inc. now owns 7,054 shares of the company's stock worth $261,000 after purchasing an additional 1,694 shares in the last quarter. Squarepoint Ops LLC lifted its holdings in Twist Bioscience by 192.8% during the 2nd quarter. Squarepoint Ops LLC now owns 71,708 shares of the company's stock worth $2,638,000 after purchasing an additional 47,221 shares in the last quarter. Geneos Wealth Management Inc. purchased a new stake in Twist Bioscience during the 2nd quarter worth about $97,000. Soleus Capital Management L.P. purchased a new stake in Twist Bioscience during the 2nd quarter worth about $13,038,000. Finally, Man Group plc lifted its holdings in Twist Bioscience by 5.3% during the 2nd quarter. Man Group plc now owns 106,509 shares of the company's stock worth $3,918,000 after purchasing an additional 5,348 shares in the last quarter.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.